Insights into the inhibitory mechanisms of NADH on the αγ heterodimer of human NAD-dependent isocitrate dehydrogenase

Yabing Liu1, Lejia Hu1, Tengfei Ma2, Jun Yang3 & Jianping Ding2,3

Human NAD-dependent isocitrate dehydrogenase (NAD-IDH) catalyzes the oxidative decarboxylation of isocitrate in the citric acid cycle. In the αβγ heterotetramer of NAD-IDH, the γ subunit plays the regulatory role and the β subunit the structural role. Previous biochemical data have shown that mammalian NAD-IDHs can be inhibited by NADH; however, the molecular mechanism is unclear. In this work, we show that the αβ, αγ and αβγ enzymes of human NAD-IDH can be inhibited by NADH, and further determine the crystal structure of the αγ heterodimer bound with an Mg2+ and an NADH at the active site and an NADH at the allosteric site, which resembles that of the inactive αγMgγ heterodimer. The NADH at the active site occupies the binding site for NAD+ and prevents the binding of the cofactor. The NADH at the allosteric site occupies the binding sites for ADP and citrate and blocks the binding of the activators. The biochemical data confirm that the NADH binding competes with the binding of NAD+ and the binding of citrate and ADP, and the two effects together contribute to the NADH inhibition on the activity. These findings provide insights into the inhibitory mechanisms of the αγ heterodimer by NADH.

Isocitrate dehydrogenases (IDHs) are the enzymes that catalyze the oxidative decarboxylation of isocitrate (ICT) into α-ketoglutarate (α-KG) and CO2 while converting the coenzyme NAD+ or NADP+ into NADH or NADPH. In mammals, the mitochondria localized NAD-dependent IDHs (NAD-IDHs) are deemed to exert the catalytic role in the citric acid cycle. Mammalian NAD-IDH functions as a heterotetramer consisting of two α subunits (37 kDa), one β subunit (39 kDa), and one γ subunit (39 kDa). The α and β subunits share about 40% sequence identity, the α and γ subunits about 42% sequence identity, and the β and γ subunits about 52% sequence identity1,2. The α and β subunits form a heterodimer (αβ) and the α and γ subunits form another (αγ), and the two heterodimers are assembled into the heterotetramer (αβγ), which can be further assembled into a heterooctamer3,4.

Previous biochemical studies have shown that the enzymatic activity of mammalian NAD-IDH could be positively regulated by citrate (CIT) and ADP; and in the αβγ heterotetramer, the α subunit exerts the catalytic role, and the β and γ subunits play the regulatory roles5–11. In our previous biochemical studies, we demonstrated that the αβγ heterotetramer and the αγ heterodimer of human NAD-IDH could be activated by CIT and ADP, whereas the αβ heterodimer cannot; and the β subunit plays the structural role in the assembly and the γ subunit the regulatory role in the function of the heterotetramer12. Due to the lack of structural information about the αβγ heterotetramer, the molecular basis for the assembly of the αβγ heterotetramer and the molecular
Figure 1. Inhibitory effects of NADH on the αγ, αβ and αβγ enzymes of human NAD-IDH. The enzymatic activities of the αγ and αβγ enzymes in the presence of NADH were measured at the standard conditions with varied concentrations of NADH as described in "Methods". The activity of the αγ enzyme was determined at the same conditions except for a higher concentration of MnCl₂ (50 mM). The inhibitory effect of NADH on the activity of the enzyme is presented as percent of inhibition (I) as a function of NADH concentration.

Results and Discussion

NADH inhibits the activities of the αγ, αβ and αβγ enzymes of human NAD-IDH. The previous biochemical studies have shown that the enzymatic activity of NAD-IDH purified from bovine heart can be inhibited by NADH\(^+\); however, the inhibition mechanism is unclear. In this work, we examined the inhibition of the αβ and αγ heterodimers and the αβγ heterotetramer of human NAD-IDH by NADH and found that all these enzymes can be substantially inhibited by NADH. To understand the molecular mechanism of the NADH inhibition, we solved the crystal structure of the αγ heterodimer bound with an Mg\(^{2+}\) and an NADH at the active site and an NADH at the allosteric site. The overall structure of the αγ(29%Mg,NADH) heterodimer resembles that of the αγ(Mg\(^{2+}\)) heterodimer, representing the inactive state of the enzyme. Structure analysis shows that the bound NADH at the active site occupies the binding site for NAD\(^+\), thus preventing the binding of the cofactor; and the bound NADH at the allosteric site occupies a large portion of the binding sites for ADP and CIT, thus blocking the binding of the activators. The kinetic data confirm that the NADH binding competes with the binding of NAD\(^+\) to the active site and the binding of CIT and ADP to the allosteric site, and the two effects together contribute to the inhibition of NADH on the αγ heterodimer. These findings provide insights into the inhibitory mechanism of the αγ heterodimer by NADH.

Previous biochemical studies have also shown that the enzymatic activity of mammalian NAD-IDH could be inhibited by NADH\(^+\); however, the inhibition mechanism is unclear. In this work, we examined the inhibition of the αβ and αγ heterodimers and the αγ(29%Mg,NADH) heterotetramer of human NAD-IDH by NADH and found that all these enzymes can be substantially inhibited by NADH. To understand the molecular mechanism of the NADH inhibition, we solved the crystal structure of the αγ heterodimer bound with an Mg\(^{2+}\) and an NADH at the active site and an NADH at the allosteric site. The overall structure of the αβγ(29%Mg,NADH) heterotetramer resembles that of the αβγ(Mg\(^{2+}\)) heterotetramer, representing the inactive state of the enzyme. Structure analysis shows that the bound NADH at the active site occupies the binding site for NAD\(^+\), thus preventing the binding of the cofactor; and the bound NADH at the allosteric site occupies a large portion of the binding sites for ADP and CIT, thus blocking the binding of the activators. The kinetic data confirm that the NADH binding competes with the binding of NAD\(^+\) to the active site and the binding of CIT and ADP to the allosteric site, and the two effects together contribute to the inhibition of NADH on the αγ heterodimer. These findings provide insights into the inhibitory mechanism of the αγ heterodimer by NADH.
Table 1. Thermodynamic parameters of NADH and NAD\(^+\) binding with the \(\alpha\beta, \alpha\gamma\) and \(\alpha\beta\gamma\) enzymes of human NAD-IDH analyzed by ITC at 20 °C. *Abbreviations: \(K_d\) dissociation constant; ND, not detectable; WB, weak binding. **Numbers in parentheses refer to the concentrations of titrand (protein)/titrant (NADH or NAD\(^+\)) in the measurements.

| Protein | \(K_d (\mu M)^\alpha\) | \(\Delta H (kcal/mol)\) | \(T\Delta S\) | \(n\)-value |
|---------|------------------------|--------------------------|----------|-----------|
| For NADH |                        |                          |          |           |
| \(\alpha\beta\) (30 \(\mu M/0.8 \text{ mM}\)) | 4.6 ± 0.7 | -16.6 ± 0.7 | -9.03 | 1.26 ± 0.04 |
| \(\alpha\gamma\) (100 \(\mu M/4 \text{ mM}\)) | 109.0 ± 19.5 | -8.1 ± 1.3 | -2.62 | 2.19 ± 0.27 |
| \(\alpha\beta\gamma\) (30 \(\mu M/2 \text{ mM}\)) | 46.3 ± 6.5 | -21.8 ± 2.7 | -14.8 | 2.53 ± 0.25 |
| For NAD\(^+\) |                        |                          |          |           |
| \(\alpha\beta\) (200 \(\mu M/4 \text{ mM}\)) | 268.1 ± 28.4 | -5.0 ± 0.7 | -0.2 | 1.14 ± 0.11 |
| \(\alpha\gamma\) (100 \(\mu M/4 \text{ mM}\)) | ND | ND | ND | ND |
| \(\alpha\beta\gamma\) (100 \(\mu M/8 \text{ mM}\)) | WB | WB | WB | WB |

Overall structure of the \(\alpha\mathrm{Mg}^++\text{NADH}_{\alpha\gamma}\) heterodimer. To understand the inhibitory mechanism of the \(\alpha\gamma\) heterodimer by NADH, we solved the crystal structure of the \(\alpha\gamma\) heterodimer bound with an \(\mathrm{Mg}^2+\) and an NADH at the active site and an NADH at the allosteric site (\(\alpha\mathrm{Mg}^++\text{NADH}_{\alpha\gamma}\)) at 2.4 Å resolution using the molecular replacement method (Table 2) (Fig. 3a). The structure belongs to space group \(P3_121\) containing one \(\alpha\gamma\) heterodimer per asymmetric unit. The majority of the residues in both \(\alpha\) and \(\gamma\) subunits are well defined except for a few N-terminal and C-terminal residues due to poor electron density. There is evident electron density for both \(\mathrm{Mg}^2+\) and NADH at the active site and an NADH at the allosteric site (Fig. 3b). The bound metal ion was interpreted as an \(\mathrm{Mg}^2+\) with a reasonable B-factor as there was 50 mM \(\mathrm{Mg}^2+\) in the crystallization solution. The bound ligands were interpreted as NADH because there is only NADH but no oxidizing agent in the crystallization solution and the NADH could not be oxidized into \(\text{NAD}^+\) in the crystallization. The NADH at the active site has a higher B-factor than the NADH at the allosteric site and the protein, indicating a lower occupancy or higher flexibility. This may suggest that the active site has a relatively lower affinity for NADH than the allosteric site.

Structure of the active site. The active site resides in the deep cleft formed largely by the small and large domains of the \(\alpha\) subunit and the small domain of the \(\gamma\) subunit, which consists of the binding sites for ICT, \(\mathrm{Mg}^2+\), and NAD\(^+\) adjacent to the ICT-binding site (Fig. 3a). Previous biochemical and structural studies have shown that in the \(\alpha\gamma\) heterodimer, Asp230\(^\alpha\), Asp234\(^\alpha\) and Asp215\(^\gamma\) (superscripts “\(\alpha\)” and “\(\gamma\)” denote the \(\alpha\) subunit and \(\gamma\) subunit, respectively) form the Mg\(^2+\)-binding site, and Thr74\(^\alpha\), Ser82\(^\alpha\), Arg88\(^\alpha\), Arg98\(^\alpha\), Arg119\(^\alpha\), Tyr126\(^\alpha\) and Asp230\(^\alpha\) form the ICT-binding site. The residues of the \(\alpha\) subunit are unvaried in the corresponding subunits of all NAD-IDHs (Fig. 3c).

In the \(\alpha\mathrm{Mg}^++\text{NADH}_{\alpha\gamma}\) heterodimer, the key residues composing the ICT- and Mg\(^2+\)-binding sites and particularly the side chains of Tyr126\(^\alpha\) and Asp230\(^\alpha\) exhibit similar conformations as those in the inactive \(\alpha\mathrm{Mg}^++\text{NADH}_{\alpha\gamma}\) heterodimer (PDB code 5GRR) but different conformations from those in the active \(\alpha\mathrm{Mg}^++\text{Mg}^2++\text{CT}+\text{ADP}\) heterodimer (PDB code 5GRE) (Fig. 4a). Specifically, like in the \(\alpha\mathrm{Mg}^++\) structure, Tyr126\(^\alpha\) forms a hydrogen bond via its side chain with the side chain of Arg119\(^\alpha\) and a cation-π interaction with the side chain of Arg88\(^\alpha\) and Asp230\(^\alpha\) forms a coordination bond via its side chain with the Mg\(^2+)\). In contrast, in the \(\alpha\mathrm{Mg}^++\text{Mg}^2++\text{CT}+\text{ADP}\) structure, the side chain of Tyr126\(^\alpha\) is oriented towards the ICT-binding site and the side chain of Asp230\(^\alpha\) is oriented towards the side chain of Tyr126\(^\alpha\), and consequently the side chains of these two residues forms a hydrogen bond...
and additionally both of the side chain and main chain of Asp230 make a coordination bond with the Mg$^{2+}$. These results indicate that the active site in the αMg$^{2+}$NADH$\gamma$NADH heterodimer assumes an inactive conformation as that in the αMg$^{2+}$γheterodimer, corresponding to the enzymatic state with a high $S_{0.5,ICT}$ (the concentration of the substrate ICT needed to 0.5* $V_{max,ICT}$, where “$V_{max,ICT}$” is the maximal velocity in the presence of saturated ICT)\cite{12,13}.

In the αMg$^{2+}$NADH$\gamma$NADH structure, the NAD$^+$-binding site is bound with an NADH: the adenine moiety of the NADH is located at the deep pocket of the active site and the nicotinamide moiety positioned in close to the ICT-binding site. The NADH makes hydrogen-bonding interactions with a number of residues from the large domain of the α subunit, including Lys69, Thr74, Asn84, Glu260, His263, Gly264, Thr265, Asp268, and Asn276 (Fig. 4b). Specifically, the nicotinamide moiety of NADH makes hydrogen-bonding interactions with the side chains of Lys69, Asn84, and Glu260; the nicotinamide ribose moiety forms hydrogen bonds with the main chains of Thr74 and Thr265; the phosphate and the ribose 2'-OH of the adenosine moiety form a hydrogen bond with the main chain of Gly264 and the side chain of Asp268, respectively; and the adenine moiety forms a hydrogen bond with the side chain of His263 and two hydrogen bonds with the main chain of Asn276.

**Figure 2.** Binding of NADH (a) and NAD$^+$ (b) with the αγ, αβ and αβγ enzymes of human NAD-IDH measured by ITC at 20°C. The concentrations of titrant (protein) and titrant (NADH or NAD$^+$) in the measurements are listed in Table 1. The corrected heat change was obtained by subtracting the heat of dilution from the measured heat change, and the normalized corrected heat change of injectant was plotted against the molar ratio of titrant vs. titrand. The values of thermodynamic parameters were derived from the titration curve by fitting the experimental data using a nonlinear least-squares method with the single set of binding sites model and are summarized in Table 1. The dissociation constant $K_d$ values are shown in the figure.
Sequence alignment shows that the residues involved in the NADH binding are also strictly conserved in the catalytic subunits of all NAD-IDHs (Fig. 3c). Structural comparison also shows that these residues assume very similar conformations as those in both the inactive \( \alpha \text{Mg}\gamma \text{heterodimer} \) and the active \( \alpha \text{Mg}\gamma \text{Mg}^+\text{CIT}^+\text{ADP} \text{heterodimer} \), indicating that in the absence of ICT, the active site of the \( \alpha\gamma \text{heterodimer} \) can bind NAD\(^+\)/NADH, and the NAD\(^+\)/NADH binding induces no notable conformational changes at the active site. These results concur with the previous biochemical data showing that NAD-IDH adopts an ordered mechanism with the NAD\(^+\) binding prior to the ICT binding,\(^3\) and our biochemical data showing that NADH can compete with NAD\(^+\) to bind at the active site and inhibits the activity of the \( \alpha\gamma \text{heterodimer} \) (Figs 1 and 2, and Table 1).

Comparison with the structures of \textit{Acidithiobacillus thiooxidans} NAD-IDH and NADP-IDHs also allows us to identify the residues involved in the recognition of NAD\(^+\) and NADP\(^+\), which differ only between the 2’-hydroxyl group of the adenosine ribose of NAD\(^+\) and the 2’-phosphomonoester group of the adenosine ribose of NADP\(^+\). In the \( \alpha\text{Mg}\text{NADH}_{\gamma}\text{NADH} \) structure, Asp268\(\alpha\) makes a hydrogen-bonding interaction with the 2’-hydroxyl group of the adenosine ribose, and in the \textit{A. thiooxidans} NAD-IDH structure (PDB code 2D4V), the equivalent residue Asp357 forms two hydrogen-bonding interactions with the 2’- and 3’- hydroxyl groups of the adenosine ribose of NAD\(^+\).\(^15\) Sequence alignment shows that this Asp is invariable in the corresponding subunits of human, \textit{Xenopus laevis}, and \textit{Danio rerio} NAD-IDHs (Fig. 3c). However, in the NADP-bound human cytosolic NADP-IDH structure (PDB code 1T0L), Arg314 and His315 make hydrogen-bonding interactions with the 2’-phosphomonoester group of the adenosine ribose of NADP\(^+\) and the equivalent residues are also unvaried in all the dimeric eukaryotic NADP-IDHs\(^17\). These results indicate that Asp268\(\alpha\) of human NAD-IDH (or the equivalent of other NAD-IDHs) is the specificity determinant for NAD\(^+\) against NADP\(^+\), and Arg314 and His315 of human cytosolic NADP-IDH (or the equivalents of other NADP-IDHs) are the specificity determinants for NADP\(^+\) against NAD\(^+\).

### Table 2. Statistics of X-ray diffraction data and structure refinement. \(^a\)Numbers in parentheses refer to the highest resolution shell. \(^b\)\( R_{\text{merge}} = \sum_{hkl} \sum_{i} I_{hkl} - \langle I(hkl) \rangle / \sum_{hkl} \sum_{i} I_{hkl} \). \(^c\)R factor = \( \sum |F_o| - |F_c| / \sum |F_o| \).

| Data collection | \( \alpha \text{Mg}\text{NADH}_{\gamma}\text{NADH} \) |
|----------------|------------------------------------------|
| Wavelength (Å) | 0.9785 |
| Space group | \(P3_21\) |
| \( a, b \) (Å) | 118.0 |
| \( c \) (Å) | 142.1 |
| Resolution (Å) | 50.0–2.40 (2.49–2.40)\(^a\) |
| Observed reflections | 449,533 |
| Unique reflections (|I/|σ(I)| > 0) | 45,428 |
| Average redundancy | 9.9 (8.9) |
| Average | 22.6 (2.8) |
| Completeness (%) | 100.0 (100.0) |
| \( R_{\text{merge}} \) (%) | 12.1 (65.3) |

### Refinement and structure model

| No. of reflections (Fo > 0σ(Fo)) | 45,386 |
| Working set | 43,063 |
| Test set | 2,323 |
| R factor/R\text{free} factor (%) | 21.1/23.6 |
| Total protein atoms | 5,048 |
| Total ligand atoms | 89 |
| Average B factor (Å\(^2\)) | 63.9 |
| Mg (active site) | 52.6 |
| NADH (active/allosteric site) | 129.3/70.8 |
| Water | 54.3 |

### RMS deviations

| Bond lengths (Å) | 0.008 |
| Bond angles (°) | 1.3 |
| Ramachandran plot (%) | 96.5 |
| Allowed | 3.5 |

Structure of the allosteric site. The allosteric site resides in the deep cleft formed largely by the small and large domains of the \( \gamma \) subunit as well as the small domain of the \( \alpha \) subunit, which comprises the binding sites for CIT, Mg\(^2+\), and ADP adjacentaly (Fig. 3a). Surprisingly, in the \( \alpha\text{Mg}\text{NADH}_{\gamma}\text{NADH} \) structure, there is an NADH bound...
Figure 3. Structure of the \(\alpha\text{Mg}^2+\text{NADH}_\gamma\text{NADH}\) heterodimer of human NAD-IDH. (a) Overall structure of the \(\alpha\text{Mg}^2+\text{NADH}_\gamma\text{NADH}\) heterodimer in two different views. Left: view in perpendicular to the pseudo 2-fold axis of the \(\alpha\gamma\) heterodimer. Right: view along the pseudo 2-fold axis of the \(\alpha\gamma\) heterodimer. The color-coding schemes of individual domains of the \(\alpha\) and \(\gamma\) subunits are shown above. The bound NADHs are shown in space-filling models, and the bound \(\text{Mg}^2+\) ion as a green sphere. (b) Representative simulated annealing composite omit maps (contoured at 1.0\(\sigma\) level) of the bound NADHs in the \(\alpha\text{Mg}^2+\text{NADH}_\gamma\text{NADH}\) structure. Left: \(\text{Mg}^2+\) and NADH at the active site. Right: NADH at the allosteric site. The NADH is shown in ball-and-stick model and the \(\text{Mg}^2+\) with a green sphere, respectively. (c) Structure-based sequence alignment of the \(\alpha\) and \(\gamma\) subunits of human NAD-IDH with several representative NAD-IDHs. Homo sapiens NAD-IDH: HsIDH3; S. cerevisiae NAD-IDH: ScIDH; Xenopus laevis NAD-IDH: XlIDH3; Danio rerio NAD-IDH: DrIDH3; Acidithiobacillus thiooxidans NAD-IDH: AtIDH. The secondary structures of the \(\alpha\) and \(\gamma\) subunits in the \(\alpha\text{Mg}^2+\text{NADH}_\gamma\text{NADH}\) structure are placed on the top of the alignment. Invariant residues are highlighted by shaded red boxes and conserved residues by open blue boxes. The residues corresponding to those composing the ICT-binding site and the NAD-binding site in the \(\alpha\gamma\) heterodimer of human NAD-IDH are highlighted with green and blue triangles, respectively.
Figure 4. Structures of the active site and the allosteric site in the αMg\text{\textsuperscript{2+}}NADH\text{\textsuperscript{\gamma}}NADH heterodimer. (a) Comparison of the ICT- and Mg\text{\textsuperscript{2+}}-binding sites in the αMg\text{\textsuperscript{2+}}NADH\text{\textsuperscript{\gamma}}NADH (salmon), αMg\text{\textsuperscript{\gamma}} (cyan, PDB code: 5GRH) and αMg\text{\textsuperscript{\gamma}}Mg\text{\textsuperscript{2+}}CIT\text{\textsuperscript{+}}ADP (slate, PDB code: 5GRE) structures. The residues composing the active site are shown in stick models, and the metal ion and water molecules as spheres. For clarity, only the coordination bonds of the metal ion in the αMg\text{\textsuperscript{2+}}NADH\text{\textsuperscript{\gamma}}NADH structure are indicated with dashed lines. (b) Comparison of the NAD\textsuperscript{\textsuperscript{+}}/NADH-binding site at the active site in the αMg\text{\textsuperscript{2+}}NADH\text{\textsuperscript{\gamma}}NADH (salmon), αMg\text{\textsuperscript{\gamma}}, αMg\text{\textsuperscript{\gamma}}Mg\text{\textsuperscript{2+}}CIT\text{\textsuperscript{+}}ADP (slate), and A. thiooxidans NAD-IDH (green, PDB code: 2D4V) structures. For clarity, only the NADH in the αMg\text{\textsuperscript{2+}}NADH\text{\textsuperscript{\gamma}}NADH structure is shown in stick model, and its hydrogen-bonding interactions with the surrounding residues are indicated with dashed lines. (c) Structure of the allosteric site in the αMg\text{\textsuperscript{2+}}NADH\text{\textsuperscript{\gamma}}NADH structure. The NADH is shown in stick model, and its hydrogen-bonding interactions with the surrounding residues are indicated with dashed lines. (d) Comparison of the allosteric site in the αMg\text{\textsuperscript{2+}}NADH\text{\textsuperscript{\gamma}}NADH (left) and αMg\text{\textsuperscript{\gamma}}Mg\text{\textsuperscript{2+}}CIT\text{\textsuperscript{+}}ADP (right) structures. The protein is shown with electrostatic potential surface, the bound NADH, CIT and ADP are shown with ball-and-stick models, and the Mg\text{\textsuperscript{2+}} with a green sphere. The NADH occupies a large
portion of the binding sites for CIT, Mg\(^{2+}\) and ADP in the γ subunit. (e) Comparison of the allosteric site in the \(\alpha_{Mg}\cdot\alpha_{NADH}\cdot\alpha_{NADH}\) (salmon), \(\alpha_{Mg}\cdot\gamma\) (cyan), and \(\alpha_{Mg}\cdot\alpha_{ADP}\) (slate) structures. The bound CIT in the \(\alpha_{Mg}\cdot\alpha_{ADP}\) structure is shown in stick model and colored in gray, the metal ion is shown as a green sphere, and the hydrogen-bonding interactions between CIT and the surrounding residues are indicated with black dashed lines. The hydrogen-bonding interactions between Arg97G-Tyr135G and between Asn78G-Arg272G in the \(\alpha_{Mg}\cdot\alpha_{NADH}\cdot\alpha_{NADH}\) structure are indicated with red dashed lines. (f) Comparison of the heterodimer interface in the \(\alpha_{Mg}\cdot\alpha_{NADH}\cdot\alpha_{NADH}\) (salmon), \(\alpha_{Mg}\cdot\gamma\) (cyan), and \(\alpha_{Mg}\cdot\alpha_{ADP}\) (slate) structures. Left: the heterodimer interface in the \(\alpha_{Mg}\cdot\alpha_{NADH}\cdot\alpha_{NADH}\) (salmon) and \(\alpha_{Mg}\cdot\gamma\) (cyan) structures. Right: the heterodimer interface in the \(\alpha_{Mg}\cdot\alpha_{ADP}\) (slate) structure. The hydrogen-bonding interactions between the N-terminal of the \(\alpha^{7A}\) and \(\alpha^{7G}\) helices and the \(\beta^{7A}\) and \(\beta^{7G}\) strands in the \(\alpha_{Mg}\cdot\alpha_{ADP}\) structure are indicated with dashed lines.

at the allosteric site, which occupies a large portion of the allosteric site. Compared with the \(\alpha_{Mg}\cdot\alpha_{ADP}\) structure, the ADP moiety and nicotinamide-ribose moiety of NADH occupy fully the ADP-binding site and the nicotinamide moiety of NADH occupies the Mg\(^{2+}\)-binding site and part of the CIT-binding site, making extensive hydrophilic and hydrophobic interactions with the surrounding residues (Fig. 4c,d). Specifically, the adenine moiety forms numerous hydrophobic interactions with Ile26G, Pro252G, Gly253G, Ile278G and Ala284G, and additionally two hydrogen bonds with the main chain of Asn285G; the adenosine phosphate forms two hydrogen bonds with the main chain and side chain of Ser277G and a hydrogen bond with the main chain of Lys276G; the nicotinamide phosphate forms one hydrogen bond each with the main chain of Gly275G and the side chain of Asn273G; the nicotinamide ribose moiety forms three hydrogen bonds with the main chain and side chain of Thr81G, and additionally one hydrogen bond each with the side chain of Glu80G and the main chain of Thr274G; and the nicotinamide moiety forms one hydrogen bond each with the side chain of Asp206G.

Interestingly, detailed structural comparisons show that the residues making direct interactions with NADH at the allosteric site adopt very similar conformations to those in the \(\alpha_{Mg}\cdot\gamma\) structure instead of those in the \(\alpha_{Mg}\cdot\alpha_{ADP}\) structure (Fig. 4e,f). In other words, the CIT-binding induced conformational changes at the allosteric site and the heterodimer interface are not observed in the \(\alpha_{Mg}\cdot\alpha_{NADH}\) structure. Particularly, in the \(\alpha_{Mg}\cdot\alpha_{NADH}\) structure, the hydrogen-bonding interactions between the side chains of Arg97G and Tyr135G and between the side chains of Asn78G and Arg272G at the allosteric site are retained, and thus all the side chains of these residues are oriented outwards from the CIT-binding site. In addition, the N-terminal regions of the \(\alpha^{7A}\) and \(\alpha^{7G}\) helices at the heterodimer interface assume loop conformation instead of helical conformation, and make no hydrogen-bonding interactions with the \(\beta^{7A}\) and \(\beta^{7G}\) strands of the clasp \(\beta\)-sheet. These results indicate that NADH can bind to the allosteric site, which blocks the binding of the activators ADP and CIT, and the NADH binding induces no notable conformational changes at the allosteric site and the heterodimer interface and hence cannot activate the enzyme.

**Functional role of the NADH binding.** Our biochemical data show that the \(\alpha_{\gamma}\) heterodimer contains at least two binding sites for NADH (Table 1). Consistently, our structural data confirm that the \(\alpha_{\gamma}\) heterodimer has two NADH-binding sites with one at the active site and the other at the allosteric site (Fig. 3). Previous biochemical studies suggested that the inhibitory effect of NADH is through its binding to the active site, which impedes the NAD\(^{+}\) binding and thus inhibits the enzymatic activity. Indeed, our biochemical data show that NADH has an evident inhibitory effect on the activity of the \(\alpha_{\gamma}\) heterodimer with an IC\(_{50}\) of 82.7 ± 6.0 μM at the standard conditions (Fig. 1). Furthermore, in the presence of 50 μM and 100 μM NADH (corresponding to 30% and 60% inhibition of the activity), the \(S_{50,NAD}\) of the enzyme (the concentration of NAD\(^{+}\) needed to reach 0.5 \(V_{\text{max}}\text{NAD}^{+}\)) is substantially increased from 0.267 ± 0.002 mM to 0.690 ± 0.080 mM (by 2.6 folds) and 1.13 ± 0.12 mM (by 4.2 folds), respectively; however, the \(V_{\text{max}}\text{NAD}^{+}\) at the saturation concentration of NAD\(^{+}\) is only slightly decreased (Fig. 5a). These results indicate that the NADH binding competes with the NAD\(^{+}\) binding, which is concurrent with the structural data showing that NADH can bind to the NAD\(^{+}\)-binding site, and in the absence of the CIT and ADP activation, the inhibitory effect of NADH can be almost completely reversed by high concentration of NAD\(^{+}\). To investigate the functional role of NADH binding at the allosteric site, we examined the effect of NADH binding on the activation of CIT at the subsaturating substrate (ICT) conditions with varied concentrations of CIT (Fig. 5b). In the absence of NADH, the \(\alpha_{\gamma}\) heterodimer has a \(S_{50,CIT}\) of 1.56 ± 0.06 mM (the CIT concentration needed to reach 0.5 \(V_{\text{max}}\text{CIT}\)) where \(V_{\text{max}}\text{CIT}\) is the maximal velocity in the presence of saturated CIT concentration and \(V_{99}\) is the initial velocity in the absence of CIT) and CIT has an evident activation effect on the enzyme with a \(V_{\text{max}}\text{CIT}\) of 6.58 ± 0.14 μmol/min/mg. In the presence of 50 μM and 100 μM NADH, the \(S_{50,CIT}\) of the enzyme is slightly increased to 2.07 ± 0.07 mM and 2.19 ± 0.05 mM, but the \(V_{\text{max}}\text{CIT}\) at the saturated CIT concentration is markedly decreased to about 66% and 40% of that in the absence of NADH, respectively. These results indicate that the NADH binding slightly decreases the binding of CIT at the allosteric site and thus increases the CIT concentration for activation, but the activation of CIT alone cannot fully reverse the inhibitory effect of NADH, which could be attributed to the binding of NADH to the active site. As the ADP activation is dependent on and synergistic with the binding of CIT\(^{12,13}\), we examined the effect of NADH on the ADP activation in the presence of 1 mM CIT (Fig. 5c). As expected, in the absence of NADH, the activity of the \(\alpha_{\gamma}\) heterodimer is markedly increased by addition of ADP and CIT, and the enzyme exhibits a \(S_{50,ADP}\) of 0.056 ± 0.004 mM [the ADP concentration needed to reach 0.5 \(V_{\text{max}}\text{ADP}\)]; where \(V_{\text{max}}\text{ADP}\) is the maximal velocity in the presence of saturated ADP concentration and \(V_{99}\) is the initial velocity in the absence of ADP] and \(V_{\text{max}}\text{ADP}\) of 14.1 ± 0.2 μmol/min/mg. In the presence of 50 and 100 μM NADH, the \(S_{50,ADP}\) is increased to 0.113 ± 0.008 mM (by 2.0 folds) and 0.206 ± 0.014 mM (by 3.7 folds), respectively, whereas the \(V_{\text{max}}\text{ADP}\) is only slightly decreased to 13.0 ± 0.1 μmol/min/mg.
Molecular mechanism of the inhibition of the αγ heterodimer by NADH. The previous biochemical studies have shown that the activity of the purified bovine heart NAD-IDH can be inhibited by NADH; however, the molecular mechanism is unclear. It was suggested that the inhibitory effect of NADH is through its binding to the active site, which impedes the binding of NAD⁺ and thus impairs the enzymatic activity. In this work, we demonstrate that the αβγγ heterotetramer has the highest binding affinity for both NADH and NAD⁺ followed by the αβγγ heterotetramer and then the αγ heterodimer. We further solved the structure of the αγ heterodimer bound with an Mg²⁺ and an NADH at the active site and an NADH at the allosteric site and performed the kinetic studies. The structural and biochemical data together reveal the inhibitory mechanisms of NADH on the αγ heterodimer.

Our structural data show that NADH can bind to the NAD-binding site, which competes with the binding of the cofactor NAD⁺ at the active site. Consistently, our biochemical data show that the NADH binding markedly increases the $S_{0.5,NAD}$ of the enzyme, and hence inhibits the activity of the enzyme. In addition, our structural data show that NADH can also bind to the allosteric site to occupy a large portion of the binding sites for the activators CIT and ADP, and this binding competes with the binding of CIT and ADP and thus impedes the activation of the enzyme. Indeed, our biochemical data show that the NADH binding increases the concentrations of the activators for activation, and hence inhibits the activity of the enzyme. These two effects together contribute to the inhibition of NADH on the enzymatic activity of the αγ heterodimer. This mechanism is very likely applicable to the αβγγ heterotetramer and thus the ligands might have different binding modes. Further structural and functional studies of the αβγγ heterotetramer will resolve this issue and provide a complete understanding of the molecular basis for the assembly and the allosteric regulation mechanism of the αβγγ heterotetramer.

Methods
Cloning, expression, and purification. Preparations of the αβ and αγ heterodimers and the αβγγ heterotetramer of human NAD-IDH followed the method described previously. In particular, to obtain the αγ heterodimer, the human DNA fragments corresponding to the α and γ subunits of human NAD-IDH were amplified by PCR and cloned into the pQlinkN co-expression plasmid following the standard procedure. For purification purpose, the C-terminal end of the γ subunit was attached with a TEV protease cleavage site followed by a His₆ tag. The constructed pQlinkN-αγ-TEV-His₆ plasmid was transformed into E. coli BL21(DE3) Codon-Plus strain (Novagen), and the bacterial cells were cultured in LB medium supplemented with 100 μg/ml ampicillin at 37°C until OD₆₀₀ reached 0.5. The protein expression was induced by adding 0.4 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 23°C for 20 hr. The bacterial cells were harvested by centrifugation and resuspended in a lysis...
buffer [50 mM HEPES (pH 7.4), 200 mM NaCl, 0.2 mM MnCl₂, 10% (v/v) glycerol, 7.2 mM β-ME, and 1 mM PMSF], and then lyzed by sonication on ice. Protein purification was first carried out by affinity chromatography using an Ni-NTA column (Qiagen). The C-terminal His₆-tag of the γ subunit was cleaved with the TEV protease by dialysis overnight against the lysis buffer. The protein mixture was reloaded on an Ni-NTA column and washed with the lysis buffer containing 10 mM imidazole, and the eluent was further purified by gel filtration using a Superdex 200 10/300 GL column (GE Healthcare). The purified protein was of high purity (above 95%) as analyzed by SDS-PAGE (12%), and stored in the storage buffer (10 mM HEPES, pH 7.4, 200 mM NaCl, and 5 mM β-ME) for the structural and biochemical studies.

Crystallization, diffraction data collection and structure determination. To obtain the αγ heterodimer bound with NADH, the protein solution (10 mg/ml) was incubated with NADH (final concentration of 10 mM) at 4°C before crystallization. Crystallization screening was carried out using the hanging drop vapor diffusion method, and crystals of the αβγβ₆-NAD⁺,NADH heterodimer were grown at 20°C from drops consisting of 1 μl each of the protein solution and the reservoir solution [0.1 M HEPES (pH 7.5), 50 mM MgCl₂, and 30% (v/v) PEGMME 550]. Diffraction data were collected from a flashed-cooled crystal at 100 K at beamline 19U1 of NFPS, China, and processed, integrated and scaled together using HKL3000 19. The flashed-cooled crystal was prepared by soaking the crystal into the cryo-protectant containing the reservoir solution mixed with 20% ethyl glycol and then quickly dipping into liquid N₂. Crystallographic statistics are listed in Table 2.

The αβγβ₆-NAD⁺,NADH structure was solved with the molecular replacement (MR) method as implemented in program Phaser 20 using the αβγβ₆-(PDB code 5GRH) 19 as the search model. Structure refinement was performed using programs Phenix 21 and REFMAC5 22, and manual model building with program Coot 23. Structural analyses were performed using programs in the CCP4 suite 24 and the PISA server 25. The structure figures were generated using PyMol 26 and the structure-based sequence alignment figure using ESPript 3.0 27. Statistics of the structure refinement and the quality of the structure model are also listed in Table 2.

Enzymatic activity assays and kinetic analyses. The enzymatic activity assay was carried out using a method as described previously 11. The activity of the enzyme was determined by monitoring the reduction of NAD⁺ to NADH over time at the specific absorption wavelength of NADH (340 nm) using a Beckman Coulter DU 800 spectrophotometer. The standard reaction solution consisted of 33 mM Tris-acetate (pH 7.4), 2 mM DL-ICT, 2 mM Mn²⁺, and 1 mM NAD⁺ in a total volume of 1 ml. The catalytic reaction was initiated by addition of NAD⁺. The production of NADH follows pseudo-first-order kinetics and the time course of the product appearance is well modeled by a linear function up to the time when about 10% of the total substrate was converted to the product. The initial velocity (V) was determined from the slope of a linear fit of the early time point data. The activity of the enzyme is defined as the velocity at the specific conditions, which is expressed as μmol of NADH produced per min per mg of enzyme (μmol/min/mg). All experiments were carried out at 25°C and repeated at least twice under the same conditions.

The activities of the αγ and αβγβ₆ enzymes in the presence of NADH were determined at the standard conditions with varied NADH concentrations, and the activity of the αβγβ₆ enzyme was determined at the same conditions with a higher concentration of MnCl₂ (50 mM). The inhibitory effect of NADH on the activity of the enzyme is presented as percent of inhibition (I) as a function of NADH concentration. I = (V₀ − V)/V₀ × 100, where V₀ and V were the initial velocity in the absence and presence of NADH, respectively.

To analyze the effect of NADH on the binding of the cofactor NAD⁺, the apparent kinetic parameters of the enzyme for NAD⁺ in the presence of 0, 50 and 100 μM NADH were determined at the standard conditions with varied NAD⁺ concentrations (0–20 mM). The values of the Vₘₐₓ,NAD₊ and Sₜₐₜ,NAD₊ were determined by fitting the experimental data into the Michaelis-Menten equation “V = Vₘₐₓ*[S]/(Sₜₐₜ + [S])” using program Graphpad Prism (Graphpad Software), where “Sₜₐₜ” is the NAD⁺ concentration at the velocity of 0.5 × Vₘₐₓ and “[S]” is the concentration of NAD⁺.

To analyze the effects of NADH on the binding of the activators CIT and ADP, the activation curve for CIT in the presence of 0, 50, and 100 μM NADH were determined at sub saturating substrate (ICT) conditions (33 mM Tris-acetate, pH 7.4, 0.6 mM DL-ICT, 2 mM Mn²⁺, and 3 mM NAD⁺) with varied CIT concentrations (0–10 mM), and the activation curve for ADP in the presence of 0, 50, and 100 μM NADH were determined at the same conditions with varied ADP concentrations (0–2 mM) and the presence of 1 mM CIT. The apparent kinetic parameters for CIT (or ADP) were obtained by fitting the experimental data into the non-Michaelis-Menten equation “V = V₀ = (Vₘₐₓ − V₀)*[S]/h(Sₜₕₛ + h)*h)” where “h” is the Hill coefficient, “Sₜₕₛ” is the CIT (or ADP) concentration when (V = V₀) equals to 0.5 × (Vₘₐₓ − V₀), “[S]” is the concentration of CIT (or ADP), “Vₘₐₓ” is the initial velocity in the absence of CIT (or ADP), and “Vₐₜₜ” is the maximal velocity in the presence of saturating CIT (or ADP) concentration. “Vₘₐₓ − V₀” reflects the maximal activation effect caused by addition of CIT (or ADP). The h value for CIT activation in the presence of 0, 50, and 100 μM NADH is about 2.5, 2.6, and 3.4, respectively, indicating the CIT binding exhibits significant cooperativity. The h value for ADP activation in the presence of 0, 50, and 100 μM NADH is all about 1, indicating that the ADP binding in the presence of 1 mM CIT exhibits no cooperativity. All of the values are the averages of three independent experiments with standard errors.

Isothermal titration calorimetry analyses. Isothermal titration calorimetry (ITC) measurements were performed at 20°C using an ITC200 Micro-Calorimeter Q6 (MicroCal). An initial injection of 0.4 μl titrant (NADH or NAD⁺) was discarded for each dataset to remove the effect of titrant diffusion across the syringe tip during the equilibration process. The αβγβ₆ or αβγβ₇ protein (30–200 μM) (titrant) was first dialyzed against the buffer (50 mM HEPES, pH 7.4, and 200 mM NaCl) and then placed in the sample cell with a reaction volume of 200 μl. The titrant (0.8–8 mM) was prepared in the same buffer as the titrant, and aliquots of the titrant (2 μl)
each) were injected incrementally into the sample cell at an interval of 120 sec (or 130 sec or 150 sec) with constant stirring at 750 rpm. The exact concentrations of titrant and titrant used in the measurements are listed in Table 1. For each concentration of titrant, a background titration was performed using identical titrant with the buffer solution placed in the sample cell to obtain the heat of dilution, which was subtracted from the measured heat change. The normalized corrected heat change of injectant was plotted against the molar ratio of titrant vs. titrand. The values of thermodynamic parameters were derived from the titration curve by fitting the experimental data using a nonlinear least-squares method with the single set of binding sites model implemented in MicroCal Origin software version 7.0. The dissociation constant ($K_d$) equals to reciprocal of the association constant ($K_a$).

**Protein Data Bank accession code.** The $\alpha$Mg$^2+$NAD$^+$-NADH structure has been deposited with the RCSB Protein Data Bank under accession code 5YVT.

**References**

1. Nichols, B. J., Hall, L., Perry, A. C. & Denton, R. M. Molecular cloning and deduced amino acid sequences of the gamma-subunits of rat and monkey NAD$^+$-isocitrate dehydrogenases. *Biochem J* 295, 347–350 (1993).
2. Nichols, B. J., Perry, A. C., Hall, L. & Denton, R. M. Molecular cloning and deduced amino acid sequences of the alpha- and beta-subunits of mammalian NAD$^+$-isocitrate dehydrogenase. *Biochem J* 310, 917–922 (1995).
3. Ehrlich, R. S. & Colman, R. F. Binding of ligands to half of subunits of NAD-dependent isocitrate dehydrogenase from pig heart. Binding of manganous ion, isocitrate, ADP and NAD. *J Biol Chem* 256, 1276–1282 (1981).
4. Ehrlich, R. S. & Colman, R. Separation, recombination, and characterization of dissimilar subunits of the DPN-dependent isocitrate dehydrogenase from pig heart. *J Biol Chem* 258, 7079–7086 (1983).
5. Chen, R. F. & Plaut, G. Activation and inhibition of DPN-linked isocitrate dehydrogenase of heart by certain nucleotides. *Biochemistry* 2, 1023–1032 (1963).
6. Gabriel, J. & Plaut, G. Citrate activation of NAD-specific isocitrate dehydrogenase from bovine heart. *J Biol Chem* 259, 1622–1628 (1984).
7. Cohen, P. F. & Colman, R. F. Diphosphopyridine nucleotide dependent isocitrate dehydrogenase from pig heart. Characterization of the active substrate and modes of regulation. *Biochemistry* 11, 1501–1508 (1972).
8. Soundar, S., Park, J.-H., Huh, T.-L. & Colman, R. F. Evaluation by mutagenesis of the importance of 3 arginines in $\alpha$, $\beta$, and $\gamma$ subunits of human NAD-dependent isocitrate dehydrogenase. *J Biol Chem* 278, 52146–52153 (2003).
9. Soundar, S., O'Hagan, M., Fomulu, K. S. & Colman, R. F. Identification of Mn$^2+$-binding aspartates from $\alpha$, $\beta$, and $\gamma$ subunits of human NAD-dependent isocitrate dehydrogenase. *J Biol Chem* 281, 21073–21081 (2006).
10. Bzymek, K. P. & Colman, R. F. Role of $\alpha$-Asp181, $\beta$-Asp192, and $\gamma$-Asp190 in the distinctive subunits of human NAD-specific isocitrate dehydrogenase. *Biochemistry* 46, 5391–5397 (2007).
11. Dange, M. & Colman, R. F. Each conserved active site tyr in the three subunits of human isocitrate dehydrogenase has a different function. *J Biol Chem* 285, 20520–20523 (2010).
12. Ma, T., Peng, Y., Huang, W. & Ding, J. The $b$ and $g$ subunits play distinct functional roles in the $\alpha$,$bg$ heterotetramer of human NAD-dependent isocitrate dehydrogenase. *Sci Rep* 7, 41882 (2017).
13. Ma, T., Peng, Y., Huang, W. & Ding, J. Molecular mechanism of the allosteric regulation of the ag heterodimer of human NAD-dependent isocitrate dehydrogenase. *Sci Rep* 7, 40921 (2017).
14. Gabriel, J. L. & Plaut, G. W. Inhibition of bovine heart NAD-specific isocitrate dehydrogenase by reduced pyridine nucleotides: modulation of inhibition by ADP, NAD$^+$, Ca$^{2+}$, citrate, and isocitrate. *Biochemistry* 23, 2773–2778 (1984).
15. Imada, K. et al. Structure and quantum chemical analysis of NAD$^+$-dependent isocitrate dehydrogenase: hydride transfer and cofactor specificity. *Proteins* 70, 63–71 (2008).
16. Xu, X. et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. *J Biol Chem* 279, 33946–33957 (2004).
17. Nekrutkenko, A., Hills, D. M., Patton, J. C., Bradley, R. D. & Baker, R. J. Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family. *Mol Biol Evol* 15, 1674–1684 (1998).
18. Scheich, C., Küimmel, D., Soumallakakis, D., Heinemann, U. & Büsow, K. Vectors for co-expression of an unrestricted number of proteins. *Nucleic Acids Res* 35, e43 (2007).
19. Ortomowski, Z. M. W. Processing of X-ray diffraction data collected in oscillation mode. *Method Enzymol* 276, 307–326 (1997).
20. McCoy, A. J. et al. Phaser crystallographic software. *J Appl Crystallogr* 40, 658–674 (2007).
21. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* 66, 213–221 (2010).
22. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr D Biol Crystallogr* 53, 240–255 (1997).
23. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 60, 2126–2132 (2004).
24. Winn, M. D. et al. Overview of the CCP4 suite and current developments. *Acta Crystallogr D Biol Crystallogr* 67, 235–242 (2011).
25. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. *J Mol Biol* 372, 774–797 (2007).
26. Schrodinger, LLC. *The PyMOL Molecular Graphics System, Version 1.8* (2010).
27. Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Res* 42, W320–324 (2014).

**Acknowledgements**

We are grateful to the staff members at beamline 19U1 of National Facility for Protein Science in Shanghai (NPFSS), China for technical assistance in diffraction data collection. We also thank other members of our group for helpful suggestion and discussion. This study was supported by grants from the National Natural Science Foundation of China (31530013 and 31521061) and the Chinese Academy of Sciences (XDB08010302).

**Author Contributions**

Y.L. and T.M. carried out all the experiments, and T.M. drafted the manuscript. L.H. and J.Y. participated in the study. J.D. conceived the study, contributed to the experimental design and data analyses, and wrote the manuscript.
**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2018